Allspring Global Investments
MRTX

Allspring Global Investments’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Allspring Global Investments’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-43
Closed -$2.53K – 2454
2023
Q4 		$2.53K Sell
43
-2,110
-98% -$119K ﹤0.01% 2087
2023
Q3 		$93.8K Sell
2,153
-220,584
-99% -$7.88M ﹤0.01% 2024
2023
Q2 		$8.05M Sell
222,737
-10,302
-4% -$424K 0.01% 850
2023
Q1 		$8.66M Sell
233,039
-5,243
-2% -$236K 0.01% 829
2022
Q4 		$10.8M Sell
238,282
-8,637
-3% -$559K 0.02% 767
2022
Q3 		$17.2M Sell
246,919
-5,435
-2% -$402K 0.03% 599
2022
Q2 		$16.9M Sell
252,354
-5,129
-2% -$326K 0.03% 634
2022
Q1 		$21.2M Sell
257,483
-7,707
-3% -$788K 0.03% 649
2021
Q4 		$38.9M Buy
+265,190
New +$41.2M 0.04% 513

Other funds holding MRTX

S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Allspring Global Investments's MRTX Position: Q1 2024 in Review

Allspring Global Investments sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 43 shares — an estimated $2.53K sold.

Allspring Global Investments first reported a position in MRTX in Q4 2021 and held it in 9 quarters. The position peaked at $38.9M in Q4 2021. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

  • Allspring Global Investments reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Allspring Global Investments sold 43 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $2.53K.
  • Allspring Global Investments first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2021 and held it in 9 quarters.
  • Allspring Global Investments's Mirati Therapeutics, Inc. Common Stock position peaked at $38.9M in Q4 2021.
  • 2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Allspring Global Investments's 13F filing for Q1 2024, filed 18 Apr 2024.